Close Menu

Atugen Signs Deals for RNAi Drug Manufacture, Formulation

SR Pharma said last week that its Atugen subsidiary has signed agreements for the manufacture and formulation of its lead RNAi-based cancer drug, Atu027, with Genzyme Pharmaceuticals, BioSpring, and OctoPlus Development.

According to SR Pharma, Genzyme has already completed the GMP production of two of the main components of the delivery system for Atu027, namely the cationic lipid AtuFECT and the fusiogenic lipid.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Guardian reports that the Mammalian Genetics Unit at the Harwell Institute is to close.

Scientific research itself contributes to plastic waste and isn't very sustainable, FiveThirtyEight reports.

Restaurants in the US may soon serve AquaBounty's genetically modified salmon, according to the Associated Press.

In Science this week: three studies from the Ruminant Genome Project, and more.